University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
University of Ottawa, Ottawa, Ontario, Canada.
Transfus Med Rev. 2018 Apr;32(2):89-101. doi: 10.1016/j.tmrv.2017.10.002. Epub 2017 Oct 22.
Postoperative anemia is a common occurrence in surgical patients and leads to an increased risk for allogeneic blood transfusions. The efficacy of iron therapy in treating postoperative anemia has not been firmly established. The objective of this systematic review was to evaluate the efficacy of postoperative oral and intravenous (IV) iron therapy in increasing hemoglobin levels and improving patient outcomes following elective surgery. The databases Medline, EMBASE, CENTRAL, the Transfusion Evidence Library, and ClinicalTrials.gov were searched. Eligible studies were randomized controlled trials or prospective cohorts having a control group, where postoperative oral or IV iron was administered to elective surgery patients. Primary outcomes were hemoglobin levels and patient-centered outcomes of quality of life and functioning. Secondary outcomes were the safety of postoperative iron and blood transfusion requirement. Meta-analysis using a random-effects model was performed. Seventeen relevant studies were identified, of which 7 investigated IV iron, 7 investigated oral iron, and 3 compared IV with oral iron. Postoperative oral and IV iron therapies were ineffective in improving quality of life and functioning (the Grading of Recommendations Assessment, Development and Evaluation [GRADE]: moderate-low quality). Compared with control, IV iron increased mean hemoglobin levels by 3.40 g/L (95% confidence interval [CI]: 1.18-5.62) (GRADE: moderate quality); however, this increase is likely not clinically meaningful. Overall, oral iron was ineffective in increasing hemoglobin concentrations compared with control (mean difference=0.77, 95% CI: -1.48-3.01) (GRADE: moderate quality). Postoperative iron therapy did not significantly reduce the risk of blood transfusion (relative risk=0.75; 95% CI: 0.53-1.07) (GRADE: low quality). IV iron was not associated with a significantly increased risk of adverse events (relative risk=4.50, 95% CI: 0.64-31.56). There was insufficient information to determine the risk of adverse events for postoperative oral iron. This systematic review found no evidence to support the routine use of postoperative iron therapy in all elective surgery patient populations; however, results are based largely on studies with non-iron-deficient patients preoperatively. Further research on the role of postoperative IV iron is warranted for certain high-risk groups, including patients with iron deficiency or anemia prior to surgery. This systematic review is registered in PROSPERO (CRD42017057837).
术后贫血是手术患者中常见的现象,会增加异体输血的风险。铁剂治疗术后贫血的疗效尚未得到明确证实。本系统评价的目的是评估术后口服和静脉(IV)铁剂治疗在择期手术后提高血红蛋白水平和改善患者结局方面的疗效。检索了 Medline、EMBASE、CENTRAL、输血证据库和 ClinicalTrials.gov 数据库。纳入的研究为随机对照试验或前瞻性队列研究,有对照组,其中术后给予口服或 IV 铁剂治疗择期手术患者。主要结局为血红蛋白水平和以患者为中心的生活质量和功能结局。次要结局为术后铁剂的安全性和输血需求。采用随机效应模型进行荟萃分析。确定了 17 项相关研究,其中 7 项研究 IV 铁,7 项研究口服铁,3 项研究比较 IV 与口服铁。术后口服和 IV 铁治疗在改善生活质量和功能方面无效(推荐评估、制定与评估分级[GRADE]:中低质量)。与对照组相比,IV 铁使平均血红蛋白水平升高 3.40 g/L(95%置信区间[CI]:1.18-5.62)(GRADE:中质量);然而,这种增加可能没有临床意义。总体而言,与对照组相比,口服铁在增加血红蛋白浓度方面无效(平均差异=0.77,95%CI:-1.48-3.01)(GRADE:中质量)。术后铁剂治疗并未显著降低输血风险(相对风险=0.75;95%CI:0.53-1.07)(GRADE:低质量)。IV 铁与不良事件风险增加无关(相对风险=4.50,95%CI:0.64-31.56)。关于术后口服铁的不良事件风险的信息不足。本系统评价没有发现证据支持在所有择期手术患者人群中常规使用术后铁剂治疗;然而,结果主要基于术前非缺铁患者的研究。对于某些高危人群,包括术前缺铁或贫血的患者,进一步研究术后 IV 铁的作用是必要的。本系统评价已在 PROSPERO(CRD42017057837)注册。